Wyoming's capital, a state that never expanded Medicaid and covers no GLP-1 for obesity, and a local market where every option is call-for-pricing.
Adult obesity in Cheyenne is 33.9% (CDC PLACES, BRFSS 2023) 1, almost identical to Wyoming's statewide 33.3% for the same year 2. Laramie County's seat holds 65,698 residents in a 101,060-person metro, with a 6.2% uninsured rate and a $79,813 median household income 34.
Cheyenne is Wyoming's capital and largest city, and it still has no clinic with a local address that publishes a GLP-1 price. The uninsured figure here is derived from summed ACS 2024 1-year B27010 categories rather than a single published headline stat, so treat it as directional 3.
Wyoming is one of just 10 states that has not adopted ACA Medicaid expansion, alongside Alabama, Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas and Wisconsin (KFF state-indicator data, checked Aug 2026) 11.
Its Medicaid Preferred Drug List, effective Jan. 1, 2026, does name GLP-1 medications, but never for weight loss. Wegovy is a preferred agent only with a MASH (metabolic-associated steatohepatitis) diagnosis. Zepbound is covered only under obstructive-sleep-apnea criteria (AHI above 15 in obese adults, with 6-month reauthorization requiring documented 5% weight loss and 12-month reauthorization requiring documented OSA improvement). Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza sit under a diabetes-only "Incretin Mimetics" category gated by a documented metformin trial and failure, with Ozempic capped at the 2mg diabetes dose rather than the higher weight-loss dose 12. Combined with non-expansion, that leaves lower-income Cheyenne residents with no Medicaid route to a GLP-1 prescribed for weight loss. General Wyoming Medicaid inquiries: (307) 777-7531.
Cheyenne Regional Medical Center runs a physician-referral weight-loss medication program routed through Orthopedics & Surgical Specialists at 2301 House Ave., (307) 635-2562, with a related facility, Healthy Lifestyle Medicine, at 6015 Sycamore Rd., (307) 634-9919. The page describes GLP-1-class drugs as "FDA-approved prescription medications for qualifying patients" and cites about 15% average total-body-weight loss, verified verbatim on the live page, but publishes no self-pay or cash price anywhere in the flow: a consultation is required just to learn cost 8.
Push IV & Wellness Lounge at 1000 E 15th St, (307) 298-5141, publishes prices for lipotropic and fat-burner injections, MICC $35 and Lipo-Mino Mix $45, but lists its GLP-1-adjacent "Medical Options" as unpriced, directing shoppers to call or email for semaglutide and tirzepatide pricing. This entry is flagged for reverification: an independent fact-check pass could not re-confirm the business through the search tooling available in that session, which is a tooling limit rather than a contradiction, and the street address itself checks out against OSM 9. BBB searches for medical spa, functional medicine and compounding pharmacy near Cheyenne returned zero businesses with an actual Cheyenne street address, the compounding-pharmacy search surfacing only a Walgreens 10.
Astra's price is national and does not move by city: $68/mo for semaglutide and $118/mo for tirzepatide on a 12-month plan ($816 / $1,416 billed annually). In Cheyenne, where every local option is call-for-pricing, it is the only figure a patient can compare anything against.
HRSA's live HPSA files, pulled Aug 27 to 28, 2026, show Cheyenne's city core is not itself a designated primary-care shortage area: the old "South Cheyenne" geographic Primary Care HPSA was withdrawn in 2014 and has never been replaced 5. Three designations are active in and around the city. Two rural slices of Laramie County, "Western Laramie County" (score 17, population 10,351) and the town of Pine Bluffs (score 18, population 3,354), carry active geographic Primary Care HPSAs. Cheyenne's two safety-net FQHCs, Cheyenne Health and Wellness Center and Community Action of Laramie County, Inc., each carry facility-level scores across Primary Care (23), Dental (25) and Mental Health (13 to 16) 567. A regional Mental Health geographic HPSA, "Southeast Wyoming" (score 15, population 167,813), covers the whole county inside a larger multi-county area 7. The city geography looks adequate on paper while the clinics that actually serve uninsured and underinsured residents are federally recognized as strained.
Cheyenne hosts Wyoming's largest hospital system, Cheyenne Regional Medical Center, and as the state capital the biggest concentration of physicians in Wyoming. Dedicated obesity-medicine or endocrinology specialty care is still thin: CRMC's weight-loss medication program runs through an Orthopedics & Surgical Specialists referral line rather than a standalone obesity-medicine or endocrinology clinic, and no independent obesity-medicine specialist practice was found within city limits 8. The nearest dedicated medical spas are roughly 45 minutes west in Laramie, WY, or 45 minutes to an hour south in Fort Collins, CO 10.
A remote consultation removes both the drive across the state line and the call-for-pricing step, with the price published before treatment begins.
Astra treats patients in Wyoming through state-licensed physicians.
It's hard to say for certain, because no clinic with a Cheyenne address publishes a GLP-1 price to compare against. Cheyenne Regional Medical Center's weight-loss program requires a consultation just to learn cost, and Push IV & Wellness Lounge lists its GLP-1-adjacent care as call-for-pricing. Astra's price is public and flat everywhere it operates: $68/month for semaglutide or $118/month for tirzepatide, billed on a 12-month plan ($816 or $1,416/year) — the same in Cheyenne as in every other city Astra serves.
Yes, but options are limited and pricing isn't public. Cheyenne Regional Medical Center runs a physician-referral weight-loss medication program through its Orthopedics & Surgical Specialists and Healthy Lifestyle Medicine locations, and Push IV & Wellness Lounge on E 15th St offers GLP-1-adjacent services by call or email inquiry. A Better Business Bureau search turned up no independent medical spa or compounding pharmacy with a Cheyenne street address — the nearest dedicated med spas are about 45 minutes away in Laramie, WY, or 45 minutes to an hour south in Fort Collins, CO.
No. Wyoming's Medicaid Preferred Drug List (effective Jan. 1, 2026) names these drugs only for non-obesity indications: Wegovy is preferred solely for a MASH liver-disease diagnosis, Zepbound only for moderate-to-severe obstructive sleep apnea, and the rest (Ozempic, Mounjaro, Trulicity, etc.) only for diabetes after a documented metformin trial has failed. There is no Wyoming Medicaid pathway that covers a GLP-1 prescribed for weight loss, and Wyoming is also one of just 10 states that hasn't adopted ACA Medicaid expansion.
33.9% of Cheyenne adults are living with obesity, per 2023 CDC PLACES data — almost identical to Wyoming's statewide adult rate of 33.3% (2023 BRFSS). Cheyenne isn't a local outlier; it mirrors a rate that's already high across the state.
Not in the way the federal shortage maps usually flag it — Cheyenne's city core lost its designated primary-care shortage-area status back in 2014 and hasn't been redesignated. But the strain shows up underneath that: Cheyenne's two safety-net clinics, Cheyenne Health and Wellness Center and Community Action of Laramie County, each carry their own federal shortage scores for primary care, dental, and mental health, and a regional mental-health shortage designation covers all of Southeast Wyoming. There's also no dedicated obesity-medicine or endocrinology specialty clinic in the city — CRMC's weight-loss program runs through an orthopedics referral line rather than a standalone clinic.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.